Atypical bilateral presentation in idiopathic macular telangiectasia type 1
H E Tapia Quijada1, C Mantolan Sarmiento1, M Serrano García2
1Servicio de Oftalmología, Sección de Retina, Hospital Universitario de Canarias, Tenerife, Spain.
Archivos De La Sociedad Espanola De Oftalmologia
|November 10, 2021
Summary
Idiopathic macular telangiectasia type 1 (MacTel 1) typically affects one eye. This case report details a rare bilateral MacTel 1 presentation, emphasizing multimodal imaging for diagnosis and treatment challenges.
Area of Science:
- Ophthalmology
- Medical Imaging
- Retinal Diseases
Background:
- Idiopathic macular telangiectasia type 1 (MacTel 1) is a rare retinal vascular disorder.
- It characteristically presents unilaterally, affecting central vision.
Observation:
- A 73-year-old male presented with atypical bilateral MacTel 1.
- The patient exhibited cystoid macular edema (CME).
Findings:
- Multimodal imaging, including optical coherence tomography angiography (OCTA), was crucial for differentiating MacTel 1 from MacTel 2.
- Dexamethasone implant treatment yielded limited efficacy for CME.
- Aflibercept therapy showed initial promise but was complicated by recurrences upon dose extension.
Implications:
- This case highlights the rare bilateral manifestation of MacTel 1.
- It underscores the diagnostic utility of advanced imaging techniques in retinal vascular diseases.
- The findings suggest a complex treatment response and potential for recurrence in MacTel 1 management.
Keywords:
Anti-vascular endothelial growth factorAntifactor de crecimiento endotelial vascularIdiopathic macular telangiectasia type 1(MacTel 1)OCTATelangiectasia macular idiopática tipo 1(MacTel 1)More Related Videos
10:14Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
Published on: May 26, 2023
3.7K
05:14Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
1.3K
